Beauty Health (SKIN) Reports Q1 Earnings: What Key Metrics Have to Say

For the quarter ended March 2025, The Beauty Health Company (SKIN) reported revenue of $69.6 million, down 14.5% over the same period last year. EPS came in at -$0.08, compared to -$0.10 in the year-ago quarter.

The reported revenue represents a surprise of +10.26% over the Zacks Consensus Estimate of $63.12 million. With the consensus EPS estimate being -$0.13, the EPS surprise was +38.46%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Beauty Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Total delivery systems sold: 862 compared to the 573 average estimate based on two analysts.
• Active install base: 35,014 compared to the 35,090 average estimate based on two analysts.
• Geographic Revenue- Americas: $46.30 million versus the three-analyst average estimate of $43.49 million. The reported number represents a year-over-year change of -8%.
• Geographic Revenue- EMEA: $15 million compared to the $13.60 million average estimate based on three analysts. The reported number represents a change of -21.5% year over year.
• Geographic Revenue- Asia Pacific: $8.30 million versus $6.98 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -30.8% change.
• Delivery Systems Net Sales: $20.20 million versus $14.30 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -43.6% change.
• Consumables Net Sales: $49.40 million compared to the $48.24 million average estimate based on three analysts. The reported number represents a change of +8.3% year over year.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research